Plain-English translation of NCT07153848 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →This is a real-world study following people in China who have early Alzheimer's disease or mild memory problems. Researchers want to understand whether simple blood tests can reliably track how well a medication called lecanemab works when combined with standard treatment. The study will collect blood samples and brain scans over 18 months to develop better ways to monitor this new treatment.
Currently, doctors mainly rely on expensive brain scans to see if Alzheimer's treatments are working. This research aims to find out if blood tests could do the same job more easily and affordably, making it simpler for patients to get monitored during treatment.
You likely qualify if…
You likely don't qualify if…
You would be in the study for 18 months. You'll have blood samples taken at your first visit, and then again at 3, 6, 12, and 18 months. You'll also have brain scans at 12 and 18 months to check for changes. Depending on which group you're in, you'll either take standard Alzheimer's medication alone or combine it with lecanemab (given as an infusion every two weeks). A research team will track your progress using these blood tests and scans.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
China
Sponsor
First Affiliated Hospital of Zhejiang University
Enrollment target
~400 participants
Started
July 2024
Primary completion
December 2027
Age range
45 Years – 85 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Guoping Peng, PhD
First Affiliated Hospital of Zhejiang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.